In AD research and clinical practice, CSF Aβ42 and P-tau, together with a CSF biomarker of neuronal injury (i.e., CSF total-tau or neurofilament light chain), can be used for AT(N) (amyloid, tau, neurodegeneration) in vivo classification of AD pathology17,18. Here, MAPT is linked to Alzheimer disease.